Compare · PRPO vs RVTY
PRPO vs RVTY
Side-by-side comparison of Precipio Inc. (PRPO) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRPO and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $11.33B, about 280.0x PRPO ($40.4M).
- Over the past year, PRPO is up 105.0% and RVTY is up 6.0% - PRPO leads by 99.0 points.
- PRPO has been more active in the news (3 items in the past 4 weeks vs 2 for RVTY).
- RVTY has more recent analyst coverage (19 ratings vs 0 for PRPO).
- Company
- Precipio Inc.
- Revvity Inc.
- Price
- $22.96+0.31%
- $101.42+0.00%
- Market cap
- $40.4M
- $11.33B
- 1M return
- -19.44%
- +2.09%
- 1Y return
- +105.00%
- +5.98%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 2
- Recent ratings
- 0
- 19
Precipio Inc.
Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests. The company serves oncologists, hospitals, reference laboratories, physician-office labs, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania. The company is based in New Haven, Connecticut.
Latest PRPO
- Precipio to Present at the Planet MicroCap Las Vegas
- Director Sandberg Richard A sold $22,517 worth of shares (900 units at $25.02) (SEC Form 4)
- Director Sandberg Richard A sold $77,784 worth of shares (3,134 units at $24.82), decreasing direct ownership by 20% to 8,142 units (SEC Form 4)
- Precipio Announces Q1 2026 Financial Results
- SEC Form 10-Q filed by Precipio Inc.
- Management team's 2025 market-based Options have vested
- Precipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Precipio Announces Q1-2026 Shareholder Update Call
- SEC Form DEFA14A filed by Precipio Inc.
- SEC Form DEF 14A filed by Precipio Inc.
Latest RVTY
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)
- Director Witney Frank was granted 2,280 shares, increasing direct ownership by 11% to 23,354 units (SEC Form 4)
- Director Witz Pascale was granted 2,280 shares, increasing direct ownership by 17% to 15,985 units (SEC Form 4)
- Director Barrett Peter was granted 2,280 shares, increasing direct ownership by 9% to 28,293 units (SEC Form 4)
- Director Mcmurry-Heath Michelle was granted 2,280 shares, increasing direct ownership by 54% to 6,513 units (SEC Form 4)